CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-05 | Nandabalan Krishnan Director | Option exercise | +25,889 | $0.41 | $11K | 25,889 |
| 2023-01-05 | Nandabalan Krishnan Director | Sale | −25,089 | $22.32 | $560K | 800 |
| 2023-01-05 | Nandabalan Krishnan Director | Sale | −800 | $22.93 | $18K | 0 |
| 2023-01-05 | Nandabalan Krishnan Director | Option exercise · Stock Options | −25,889 | 354,000 | ||
| 2023-01-04 | Nandabalan Krishnan Director | Option exercise | +34,111 | $0.41 | $14K | 34,111 |
| 2023-01-04 | Nandabalan Krishnan Director | Sale | −24,290 | $21.59 | $524K | 9,821 |
| 2023-01-04 | Nandabalan Krishnan Director | Sale | −9,821 | $22.21 | $218K | 0 |
| 2023-01-04 | Nandabalan Krishnan Director | Option exercise · Stock Options | −34,111 | 379,889 | ||
| 2022-12-16 | Mehta Vimal CEO and President | Option exercise | +30,000 | $0.41 | $12K | 39,957 |
| 2022-12-16 | Mehta Vimal CEO and President | Sale | −20,113 | $19.21 | $386K | 19,844 |
| 2022-12-16 | Mehta Vimal CEO and President | Sale | −9,887 | $19.92 | $197K | 9,957 |
| 2022-12-16 | Mehta Vimal CEO and President | Option exercise · Stock Option (Right to Buy) | −30,000 | 414,000 | ||
| 2022-12-15 | Mehta Vimal CEO and President | Option exercise | +30,000 | $0.41 | $12K | 39,957 |
| 2022-12-15 | Mehta Vimal CEO and President | Sale | −22,794 | $19.86 | $453K | 17,163 |
| 2022-12-15 | Mehta Vimal CEO and President | Sale | −7,206 | $20.19 | $145K | 9,957 |
| 2022-12-15 | Mehta Vimal CEO and President | Option exercise · Stock Option (Right to Buy) | −30,000 | 444,000 | ||
| 2022-11-11 | Nandabalan Krishnan Director | Option exercise | +32,550 | $0.41 | $13K | 32,550 |
| 2022-11-11 | Nandabalan Krishnan Director | Sale | −32,550 | $15.00 | $488K | 0 |
| 2022-11-11 | Nandabalan Krishnan Director | Option exercise · Stock Options | −32,550 | 414,000 | ||
| 2022-11-10 | Nandabalan Krishnan Director | Option exercise | +27,450 | $0.41 | $11K | 27,450 |
Page 21 of 27 · 521 trades